Search clinical trials for: Erlotinib placebo

Total 55152 results

Gustave Roussy, Cancer Campus, Grand Paris

Completed

Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma

Malignant Brain Tumor | Brain Stem Glioma,

France
Xinhua Hospital, Shanghai Jiao Tong University...

Completed

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
National Cancer Institute (NCI)

Completed

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditions

United States
Astellas Pharma Inc

Completed

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

Advanced Solid Tumors

United States, United Kingdom
OSI Pharmaceuticals

Completed

Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Failed Prior Chemotherapy

United States
Merrimack Pharmaceuticals

Completed

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Taiwan, United States, Canada, Korea, Republic of, Germany
The University of Hong Kong

Completed

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Lung Cancer

Hong Kong
Wu Jieping Medical Foundation
Changhai Hospital; Fudan University; RenJi Hospital; Shanghai Chest Hospital; Xinhua... and other collaborators

Unknown

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases (TRACTS)

Non-small-cell Lung Cancer | Brain Metastases

China
Hadassah Medical Organization

Unknown

C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR). (EGFR; PET/CT)

Pancreatic Cancer | Lung Cancer

Israel
Free University Medical Center

Unknown

Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Netherlands
University of Arkansas
OSI Pharmaceuticals

Terminated

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
Astellas Pharma Inc; The Kadoorie Charitable Foundations

Recruiting

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Head and Neck Cancer

United States
University of Texas Southwestern Medical Center
Genentech, Inc.; Celgene

Completed

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer | Metastatic Cancer

United States
The First Hospital of Jilin University

Recruiting

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Breast Cancer

China
Anyang Tumor Hospital

Recruiting

Anlotinib for Esophageal Cancer (AFEC)

Esophageal Cancer

China
Guangxi Zhuang Autonomous Region People's Hospital

Recruiting

Anlotinib for Hepatocellular Carcinoma (AFHC)

Liver Neoplasms

China
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Shanghai Changzheng Hospital

Recruiting

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Advanced Solid Tumor

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Phase II Study of Anlotinib in STS Patients (ALTN/STS)

Cancer

China
Second Affiliated Hospital, School of Medicine,...

Unknown

Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer

Ovarian Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Unknown

Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC) (ATAHC)

Cancer of Liver
Daiichi Sankyo Co., Ltd.
ICON Clinical Research

Completed

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Konstantin Dragnev
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Carcinoma, Non-small-cell Lung

United States
Spanish Cooperative Group for the Treatment of...
Hoffmann-La Roche

Completed

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer (GECA)

Metastatic Pancreatic Cancer

Spain
Hoffmann-La Roche

Completed

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

Australia, Belgium, Germany, Hong Kong, Canada, Spain, Taiwan, Singapore, France, United Kingdom, Austria, Italy, Croatia, Serbia, Brazil, Israel, Lithuania, Poland, Greece, Argentina, Denmark, Romania, Mexico
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
M.D. Anderson Cancer Center
OSI Pharmaceuticals

Terminated

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Skin Cancer

United States
SCRI Development Innovations, LLC
Bayer

Completed

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

Refractory Solid Tumors

United States
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline

Completed

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Lung Cancer | Lung Cancer Metastatic | Lung Adenocarcinoma | Lung Cancer Stage IV | Recurrent Lung Adenocarcinoma | Recurrent Lung Cancer

United States
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Centre Francois Baclesse
Hoffmann-La Roche; Groupe Français de Pneumo-Cancérologie

Terminated

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

NSCLC Patients With EGFR Activating Mutation

France
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
National Taiwan University Hospital

Unknown

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial (BRILLIANT)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms

Taiwan
Guangdong Association of Clinical Trials

Terminated

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation (INNOVATE)

Non-small-cell Lung Cancer

China
Heather Wakelee
Novartis; Genentech, Inc.

Terminated

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IV

United States
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
Syndax Pharmaceuticals

Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Non Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Familial Adenomatous Polyposis | Attenuated Familial Adenomatous Polyposis

United States, Puerto Rico
Peter Kozuch
Hoffmann-La Roche; Genentech, Inc.

Terminated

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Hoffmann-La Roche

Completed

A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer

China, Philippines, Malaysia
Chroma Therapeutics

Terminated

Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Io Therapeutics
Dartmouth College

Suspended

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Lung Cancer, Nonsmall Cell

United States
Hoffmann-La Roche

Completed

A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

France
Nanjing First Hospital, Nanjing Medical University

Recruiting

A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial (EASOAIPPGL)

Advanced or Metastatic Paraganglioma/ Pheochromocytoma

China
Sun Yat-sen University

Completed

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Nasopharyngeal Carcinoma

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Terminated

Anlotinib Treatment in Steroid Depenent/Refractory cGVHD

Chronic Graft-versus-host-disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Neoplasm of Bone

China

Search clinical trials for: Erlotinib placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations